Insider Buying: BioCardia (NASDAQ:BCDA) Director Buys $39,000.00 in Stock

BioCardia, Inc. (NASDAQ:BCDA) Director Simon Stertzer acquired 39,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The stock was bought at an average cost of $1.00 per share, with a total value of $39,000.00. Following the completion of the acquisition, the director directly owned 166,338 shares in the company, valued at approximately $166,338. This represents a 30.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link.

BioCardia Trading Up 6.0%

BCDA stock traded up $0.06 during trading on Wednesday, hitting $1.06. The company had a trading volume of 489,451 shares, compared to its average volume of 1,516,771. The stock has a market cap of $12.06 million, a PE ratio of -1.16 and a beta of 0.51. The business has a 50-day moving average of $1.02 and a 200-day moving average of $1.18. BioCardia, Inc. has a one year low of $0.78 and a one year high of $2.45.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Research analysts forecast that BioCardia, Inc. will post -0.76 EPS for the current year.

Hedge Funds Weigh In On BioCardia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cetera Investment Advisers acquired a new stake in shares of BioCardia in the 2nd quarter worth $40,000. DRW Securities LLC bought a new position in shares of BioCardia in the 4th quarter valued at about $72,000. Finally, Geode Capital Management LLC grew its holdings in shares of BioCardia by 70.4% in the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock valued at $83,000 after acquiring an additional 27,263 shares in the last quarter. 20.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCDA. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of BioCardia in a report on Tuesday, June 9th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, BioCardia currently has an average rating of “Hold” and an average target price of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.